AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home International Journal of Ophthalmology Article
PDF (504.1 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Clinical Research | Open Access

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy

Jung Yeon Joo1, Yong Hyun Jun2, Seong Taeck Kim3( )
Department of Pediatrics, School of Medicine, Chosun University, Gwang-ju 61453, Republic of Korea
Department of Anatomy, School of Medicine, Chosun University, Gwang-ju 61453, Republic of Korea
Department of Ophthalmology, School of Medicine, Chosun University, Gwang-ju 61453, Republic of Korea
Show Author Information

Abstract

AIM

To compare the intravitreal brolucizumab and bevacizumab injections for chronic central serous chorioretinopathy (cCSC).

METHODS

Patients with cCSC were classified into bevacizumab and brolucizumab group. The proportion of complete resolution of subretinal fluid (SRF), best-corrected visual acuity (BCVA), central macular thickness (CMT), and subfoveal choroidal thickness (SFCT) were compared between the two groups.

RESULTS

A total of 40 eyes from 40 patients with aged 34-59y were enrolled in the study. Twenty eyes in bevacizumab group (17 males) and 20 eyes (18 males) in brolucizumab group. Comparing the proportion of complete resolution of SRF, the brolucizumab group was statistically significantly higher than the bevacizumab group (P<0.05). In 1mo, CMT was significantly reduced in the brolucizumab group compared to the bevacizumab group (265±69 vs 319±70 μm; P=0.021). However, there was no significant difference in CMT between the two groups at 2 and 3mo (P>0.05).

CONCLUSION

Brolucizumab is anatomically and functionally superior to bevacizumab in the treatment of patients with cCSC.

Keywords

brolucizumabbevacizumabcentral serous chorioretinopathy

References

【1】
【1】
 
 
Crossref Google Scholar
International Journal of Ophthalmology
Volume 19 Issue 2,
February 2026
Pages 320-325
DOI: 10.18240/ijo.2026.02.14

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Joo JY, Jun YH, Kim ST. Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy. International Journal of Ophthalmology, 2026, 19(2): 320-325. https://doi.org/10.18240/ijo.2026.02.14

773

Views

35

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD
Received: 21 September 2024
Accepted: 14 March 2025
Published: 18 February 2026
© 2026 International Journal of Ophthalmology Press

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).